Latest From Gritstone Oncology
Advances in multiple scientific areas will mature into novel therapeutics, often tailored for the individual patient and increasingly curative, making biopharma an exciting place to be in 2020.
Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
Clonal neoantigen immunotherapy developer Achilles Therapeutics tells the Pink Sheet how the regulatory landscape for advanced therapies might not be as tricky as it used to be.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Company Type
- Parent & Subsidiaries
- Gritstone Oncology
- Senior Management
Andrew Allen, MD, PhD, Pres. & CEO
Jean-Marc Bellemin, EVP, CFO
Matthew Hawryluk, PhD, EVP, CBO
Karin Jooss , PhD, EVP, Research & CSO
Roman Yelensky, PhD, EVP, CTO
Raphael F Rousseau, MD, PhD, EVP, CMO
Vijay Yabannavar, PhD, EVP, Mfctng. & Tech. Operations
- Contact Info
Phone: (510) 871-6100
5858 Horton St.
Emeryville, CA 94608
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.